Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MEDI5752 + Monalizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MEDI5752 | MEDI-5752|MEDI 5752|volrustomig | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | MEDI5752 is a bispecific human IgG1 monoclonal antibody that binds PD1 (PDCD1) and CTLA4, potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2776). | |
Monalizumab | NN-8765|IPH-2201|IPH 2201|IPH2201 | NKG2A Antibody 3 | Monalizumab (IPH2201) is a humanized monoclonal antibody against NKG2A that blocks NKG2A ligand binding, which in turn induces cell-mediated immune response against cancer cells (PMID: 30503213, PMID: 31623687, PMID: 31308062). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06152523 | Phase II | MEDI5752 + Monalizumab | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer (MONAMI) | Not yet recruiting | FRA | 0 |